VALNEVA (EPA:VLA) | Finanzwire

Basculer en Français

11014	Companies
241300	Keywords
169824	Articles
129877	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 08/25/2025 at 07:00, 1 year ago

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Valneva SE announces FDA's suspension of IXCHIQ® chikungunya vaccine license in the U.S. due to serious adverse events, despite reported cases consistent with clinical trials. Sales impact to be evaluated

FDA Valneva SE Chikungunya Vaccine License Suspension Serious Adverse Events
BRIEF

published on 08/19/2025 at 10:44, 1 year ago

First Berlin Maintains Buy Rating for Valneva Amid Strong Q2 Results

BUY Rating Q2 Results Valneva SE Lyme Disease Vaccine Chikungunya Vaccine
PRESS RELEASE

published on 08/19/2025 at 10:39, 1 year ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH has published a research update on Valneva SE, maintaining their BUY rating and EUR 8.10 price target, following better-than-expected Q2/25 results and positive outlook on vaccines

BUY Rating Research Update Q2 Results Valneva SE Vaccine Outlook
BRIEF

published on 08/18/2025 at 07:05, 1 year ago

Valneva's IXCHIQ® Vaccine Authorized in Canada for Ages 12 and Older

Health Canada Valneva Vaccine Authorisation Chikungunya
PRESS RELEASE

published on 08/18/2025 at 07:00, 1 year ago

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Valneva's Chikungunya Vaccine IXCHIQ® authorized in Canada for individuals aged 12 and older. Health Canada grants marketing authorization for disease prevention

Canada Health Valneva Vaccine Chikungunya
BRIEF

published on 08/12/2025 at 07:05, 1 year 1 month ago

Valneva's Half-Year 2025 Financial Report: Growth and Strategic Moves

Financial Results Strategic Partnerships Revenue Growth Cash Management Regulatory Updates
PRESS RELEASE

published on 08/12/2025 at 07:00, 1 year 1 month ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
Valneva SE reports €97.6 million revenues in H1 2025, confirms 2025 financial outlook. Highlights financial results, R&D progress, and commercial updates

Revenues Financial Results Valneva SE R&D Progress 2025 Outlook Commercial Updates
BRIEF

published on 08/07/2025 at 07:22, 1 year 1 month ago

Valneva Obtains FDA Lift of Ban on IXCHIQ®

FDA Valneva Chikungunya IXCHIQ® Vaccine Elderly People
PRESS RELEASE

published on 08/07/2025 at 07:17, 1 year 1 month ago

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
Valneva announces FDA's removal of recommended pause on Chikungunya Vaccine IXCHIQ® in elderly individuals and updates to the Prescribing Information, following EMA's recommendation. Updates reflect Serious Adverse Events and expanded Warnings and Precaution section

FDA Valneva Chikungunya Vaccine Prescribing Information Vaccine Updates
BRIEF

published on 07/28/2025 at 13:51, 1 year 1 month ago

Valneva SE: Positive Outlook Amid Chikungunya Concerns

Biotech Valneva SE Equity Research Chikungunya Vaccine Market

Accesswire

Published on 09/17/2026 at 13:30, 32 minutes ago

UniDoc Health Equips San Juan, Puerto Rico Ambulances With Live Patient Video
Published on 09/17/2026 at 13:30, 32 minutes ago

Electric Royalties Reports Permitting Progress and New Exploration Results Across Critical Metals Royalty Portfolio
Published on 09/17/2026 at 13:00, 1 hour 2 minutes ago

Organto Foods Strengthens Scalable European Operating Platform and Launches AI Powered Operational Transformation
Published on 09/17/2026 at 13:00, 1 hour 2 minutes ago

Gold Terra Announces Fall Drilling with Three (3) Rigs Active on the Con Mine, Yellowknife, NWT
Published on 09/17/2026 at 13:00, 1 hour 2 minutes ago

NiobiumX Mining Inc. Appoints Athabasca Basin Discovery Geologist Erik Sehn to Board of Directors

View all ACCESSWIRE

EQS Group

Published on 09/17/2026 at 13:25, 36 minutes ago

Custodian Property Income REIT plc: Results of Annual General Meeting
Published on 09/17/2026 at 13:25, 36 minutes ago

CDTL Highlights E-Drive + EMB Technologies for Commercial Vehicles at IAA Transportation 2026
Published on 09/17/2026 at 13:25, 36 minutes ago

ATOME PLC: Notice of Dispute and Intent to Submit Claim to Arbitration under the UK - Paraguay Bilateral Investment Treaty ("the Treaty" or "BIT")
Published on 09/17/2026 at 13:05, 56 minutes ago

Aurzen Expands Its Presence in Germany with Launch on Joybuy, Bringing EAZZE D1 and ZIP to More Consumers
Published on 09/17/2026 at 13:03, 58 minutes ago

W&W shares move to the Scale segment

Les Echos

Published on 09/16/2026 at 20:46, 17 hours 15 minutes ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 17:45, 20 hours 17 minutes ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 20 hours 17 minutes ago

Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 7 hours ago

bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 20 hours ago

Report on the Combined General Meeting of the 10th of September 2026

View all LES ECHOS COMFI WIRE